|
 | Up a level |
Naci, Huseyin, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue and Wagner, Anita k (2024) Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology. ISSN 1470-2045
Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin, Wagner, Anita K. and Guan, Xiaodong (2024) Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45. ISSN 2666-6065
Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen and Guan, Xiaodong (2022) Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5 (8). ISSN 2574-3805
Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis and Wagner, Anita K. (2021) Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181 (12). 1596 - 1604. ISSN 2168-6106
Naci, Huseyin, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue and Wagner, Anita K. (2021) Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181 (11). 1521 - 1522. ISSN 2168-6106
